An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cerus Corporation (CERS) reported a strong first-quarter 2022 performance with total revenue of $43.0 million, reflecting a 46% year-over-year increase. Product revenue reached $37.4 million, up 60% year-over-year. The company improved its 2022 product revenue guidance to a range of $160-165 million, a 22%-26% increase over 2021. Net loss decreased to $12.3 million from $17.5 million the previous year. Notable contracts include a multi-year agreement with the American Red Cross for INTERCEPT Platelet kits, reinforcing strong demand in the U.S.
Positive
Total revenue increased by 46% year-over-year to $43.0 million.
Product revenue grew by 60% year-over-year to $37.4 million.
Increased full-year 2022 product revenue guidance to $160-165 million.
Net loss improved by $5.2 million year-over-year to $12.3 million.
Signed a multi-year contract with the American Red Cross for INTERCEPT Platelet kits.
Negative
Government contract revenue decreased by 10% year-over-year to $5.6 million.
Cash, cash equivalents, and short-term investments decreased from $129.4 million to $108.6 million.
Growth From All Geographic Regions with Results Driven by INTERCEPT Platelet Uptake in the U.S.
Total Revenue of $43.0 Million Grew 46% YoY in the First Quarter
Product Revenue of $37.4 Million Grew 60% YoY in the First Quarter
Increasing Full-Year 2022 Product Revenue Guidance Range from $157-164 Million to $160-165 Million
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022.
Recent developments and highlights include:
First quarter 2022 total revenue of $43.0 million, reflecting a 46% increase over the prior year period. Total revenue was composed of (in thousands, except %):
Three Months Ended
March 31,
2022
2021
Change
Product revenue
$
37,444
$
23,379
60
%
Government contract revenue
5,576
6,187
(10
%)
Total revenue
$
43,020
$
29,566
46
%
First quarter 2022 net loss attributable to Cerus Corporation of $12.3 million, or $0.07 per basic and diluted share, reflecting an improvement of $5.2 million over the prior year period of $17.5 million, or $0.10 per basic and diluted share, as a result of higher sales and continued operating discipline.
As of the date of this release, the Company is increasing its 2022 annual product revenue guidance range from $157-164 million to $160 million to $165 million, representing a 22% to 26% increase over full-year 2021 reported product revenue.
The Company announced that it has signed a multi-year contract for the INTERCEPT Blood System for Platelets with the American Red Cross, which is the largest producer of INTERCEPT-treated blood components in the world.
The Company and Fresenius Kabi announced a ten-year contract extension for the production of kits for the INTERCEPT Blood System. Under the new agreement, the companies will work together to expand scale at multiple Fresenius Kabi facilities, enabling manufacturing at additional locations and unlocking further economies of scale to improve the cost profile of INTERCEPT kits.
Community Blood Center of Appleton became the Company’s third blood center production partner to obtain BLA approval for the INTERCEPT Blood System for Cryoprecipitation, which is approved for the production INTERCEPT Fibrinogen Complex.
Introduced non-GAAP Adjusted EBITDA, which for the first quarter of 2022 was negative $3.7 million, compared to negative $11.5 million during the prior year period. Cerus’ non-GAAP Adjusted EBITDA is a measure the Company has disclosed to highlight the performance of its business and its progress toward achieving cashflow breakeven. For additional information, please see definitions and the reconciliation of this non-GAAP measure accompanying this release.
Cash, cash equivalents, and short-term investments were $108.6 million at March 31, 2022.
“Cerus continued to build on its leadership position in establishing pathogen reduction as a new standard of care for blood safety during the first quarter of 2022. I am pleased to report growth from all of our major geographic regions during the period, despite the significant geopolitical turmoil and economic uncertainty that has accompanied the start to this year,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “As we anticipated, demand for INTERCEPT platelet kits continues to be strong in the U.S., where hospitals are choosing pathogen reduction to comply with the FDA bacterial safety guidance.”
“In collaboration with our manufacturing partners, we continue to make solid progress scaling up our operations to unlock additional capacity in support of anticipated strong growth well into the future,” Greenman continued. “With the visibility we have for another year of robust demand for INTERCEPT products, we have opted to raise our product revenue guidance range for 2022.”
Revenue
Product revenue during the first quarter of 2022 was $37.4 million, compared to $23.4 million during the prior year period. The year-over-year growth in product revenue during the quarter came from each of the Company’s major geographic regions and was primarily driven by increased sales of INTERCEPT platelet kits in the U.S. market.
First quarter 2022 government contract revenue was $5.6 million, compared to $6.2 million during the prior year period. Reported government contract revenue is comprised of funding associated with research and development (R&D) activities related to the INTERCEPT Blood System for Red Blood Cells and sponsored efforts related to the development of next-generation pathogen reduction technology for whole blood.
Product Gross Profit & Margin
Product gross profit for the first quarter of 2022 was $19.4 million, increasing by $7.1 million over the prior year period. Product gross margin for the first quarter of 2022 was 51.7% compared to 52.5% for the first quarter of 2021, and represents an increase of approximately 60 basis points compared to the fourth quarter of 2021.
Operating Expenses
Total operating expenses for the first quarter of 2022 were $34.8 million compared to $34.9 million for the same period of the prior year. Despite having to navigate inflationary pressures, the Company was able to demonstrate financial discipline, resulting in operating leverage that is strengthening the Company’s overall financial position.
Selling, general, and administrative (SG&A) expenses for the first quarter of 2022 totaled $20.7 million, compared to $19.2 million for the first quarter of 2021. The year-over-year increase in SG&A expenses for the first quarter was tied to increased hiring and stock-based compensation.
R&D expenses for the first quarter of 2022 were $14.1 million, compared to $15.7 million for the first quarter of 2021. In the first quarter, the Company’s R&D expenses declined on a year-over-year basis as a result of various research projects reaching completion.
Net Loss Attributable to Cerus Corporation
Net loss attributable to Cerus Corporation for the first quarter of 2022 was $12.3 million, or $0.07 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $17.5 million, or $0.10 per basic and diluted share, for the first quarter of 2021.
Non-GAAP Adjusted EBITDA
Non-GAAP Adjusted EBITDA for the first quarter of 2022 was negative $3.7 million, compared to non-GAAP Adjusted EBITDA of negative $11.5 million, for the first quarter of 2021. For additional information, please see definitions and the reconciliation of this non-GAAP measure accompanying this release.
Balance Sheet & Cash Use
At March 31, 2022, the Company had cash, cash equivalents and short-term investments of $108.6 million, compared to $129.4 million at December 31, 2021.
As of March 31, 2022, the Company carried $55.0 million of notes due and a balance on its revolving line of credit of $15.0 million. The Company continues to have access to $5 million under its revolving line of credit.
For the first quarter of 2022, net cash used in operating activities totaled $21.5 million as compared to $17.5 million during the prior year period, due to changes in working capital.
Increasing 2022 Product Revenue Guidance
The Company expects full-year 2022 product revenue will be in the range of $160-165 million, representing strong growth of approximately 22%-26% compared to full-year 2021 product revenue of $130.9 million. Previously, the Company’s 2022 product revenue guidance range was $157-164 million.
Quarterly Conference Call
The Company will host a conference call at 4:30 P.M. EDT this afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).
A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 8280547. The replay will be available approximately three hours after the call through May 19, 2022.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Forward-Looking Statements
Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to Cerus’ 2022 annual product revenue guidance, including Cerus’ expectation that 2022 will be another year of strong growth led by demand for INTERCEPT platelet kits; Cerus’ plans to work together with Fresenius Kabi to expand scale at multiple facilities to enable manufacturing at additional locations, unlocking economies of scale to improve the cost profile of INTERCEPT kits; expectations regarding additional manufacturing capacity coming online in 2022; Cerus’ efforts to develop next-generation pathogen reduction technology for whole blood; expectations regarding Cerus’ strengthening overall financial position; Cerus’ continuing access to $5 million under its revolving line of credit; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) meet its 2022 annual product revenue guidance, (b) effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation, (c) grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, (d) realize meaningful and/or increasing revenue contributions from U.S. customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus’ commercial agreements with these customers, (e) effectively expand its commercialization activities into additional geographies and/or (f) realize any revenue contribution from its pipeline product candidates, whether due to Cerus’ inability to obtain regulatory approval of its pipeline programs, or otherwise; risks associated with the ultimate duration and severity of the COVID-19 pandemic and resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus’ business operations and financial results such as the current and potential additional disruptions to the U.S. and EMEA blood supply resulting from the evolving effects of the COVID-19 pandemic; risks associated with Cerus’ lack of longer-term commercialization experience with the INTERCEPT Blood System for Cryoprecipitation and in the United States generally, and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi’s efforts to assure an uninterrupted supply of platelet additive solution (PAS); risks related to how any future PAS supply disruption could affect INTERCEPT’s acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction, including IFC for the treatment and control of bleeding, and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time-consuming development and regulatory process, including the risks that (a) Cerus may be unable to comply with the FDA’s post-approval requirements for the INTERCEPT Blood System, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval(s) for the INTERCEPT Blood System, (b) additional manufacturing site Biologics License Applications necessary for Cerus to more broadly distribute the INTERCEPT Blood System for Cryoprecipitation may not be obtained in a timely manner or at all, and (c) Cerus may be unable to obtain the requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all; risks related to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from the evolving effects of the COVID-19 pandemic or otherwise in the markets where Cerus currently sells and is anticipated to sell its products; Cerus’ reliance on third parties to market, sell, distribute and maintain its products; Cerus’ ability to maintain an effective, efficient, secure manufacturing supply chain, including the risks that (a) Cerus’ supply chain could be negatively impacted as a result of the evolving effects of the COVID-19 pandemic, (b) Cerus’ manufacturers could be unable to comply with extensive FDA and foreign regulatory agency requirements, and (c) Cerus may be unable to maintain its primary kit manufacturing agreement and its other supply agreements with its third party suppliers; Cerus’ ability to identify and obtain additional partners to manufacture the INTERCEPT Blood System for Cryoprecipitation; risks associated with Cerus’ ability to access additional funds under its revolving line of credit and to meet its debt service obligations, and its need for additional funding; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus’ future capital requirements and its future revenues and other financial performance and results, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Cerus’ Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 22, 2022. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
Use of Non-GAAP Financial Measures
Cerus has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including adjusted EBITDA. We define adjusted EBITDA as income (loss) from operations as reported on the consolidated statement of operations, adjusted for depreciation, amortization, stock-based compensation, costs associated with our noncontrolling interest in our joint venture in China, and funding and direct costs associated with our government contracts. We are presenting this non-GAAP financial measure to assist investors in assessing our operating results. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Cerus’ GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Cerus’ operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.
Supplemental Tables
Three Months Ended
March 31,
2022 vs. 2021
Platelet Kit Growth
U.S.
148%
International
25%
Worldwide
91%
Change in Calculated Number of Treatable Platelet Doses*
U.S.
141%
International
28%
Worldwide
82%
* Dose treatable calculation based on the number of kits sold and the product configuration (single, double, and triple dose kits)
CERUS CORPORATION
REVENUE BY REGION
(in thousands, except percentages)
Three Months Ended
March 31,
Change
2022
2021
$
%
North America
$
22,198
$
9,664
$
12,534
130
%
Europe, Middle East and Africa
14,802
13,277
1,525
11
%
Other
444
438
6
1
%
Total product revenue
$
37,444
$
23,379
$
14,065
60
%
CERUS CORPORATION
CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
Three Months Ended
March 31,
2022
2021
Product revenue
$
37,444
$
23,379
Cost of product revenue
18,076
11,095
Gross profit on product revenue
19,368
12,284
Government contract revenue
5,576
6,187
Operating expenses:
Research and development
14,057
15,748
Selling, general and administrative
20,735
19,170
Total operating expenses
34,792
34,918
Loss from operations
(9,848
)
(16,447
)
Total non-operating expense, net
(2,360
)
(912
)
Loss before income taxes
(12,208
)
(17,359
)
Provision for income taxes
76
98
Net loss
(12,284
)
(17,457
)
Net loss attributable to noncontrolling interest
-
-
Net loss attributable to Cerus Corporation
$
(12,284
)
$
(17,457
)
Net loss per share attributable to Cerus Corporation:
Basic and diluted
$
(0.07
)
$
(0.10
)
Weighted average shares outstanding:
Basic and diluted
174,478
168,824
CERUS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
March 31,
December 31,
2022
2021
ASSETS
(unaudited)
Current assets:
Cash and cash equivalents
$
38,372
$
48,759
Short-term investments
70,185
80,600
Accounts receivable
25,645
25,129
Inventories
28,521
26,793
Prepaid and other current assets
10,089
5,821
Total current assets
172,812
187,102
Non-current assets:
Property and equipment, net
11,659
12,208
Operating lease right-of-use assets
13,665
12,971
Goodwill
1,316
1,316
Restricted cash and other assets
22,454
23,902
Total assets
$
221,906
$
237,499
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities
$
48,422
$
61,281
Debt – current
15,011
14,697
Operating lease liabilities – current
1,968
1,905
Deferred product revenue – current
1,258
673
Total current liabilities
66,659
78,556
Non-current liabilities:
Debt – non-current
54,769
54,724
Operating lease liabilities – non-current
16,787
16,260
Other non-current liabilities
3,280
2,342
Total liabilities
141,495
151,882
Stockholders' equity:
79,413
84,619
Noncontrolling interest
998
998
Total liabilities and stockholders' equity
$
221,906
$
237,499
CERUS CORPORATION
UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA
(in thousands)
Three Months Ended
March 31,
2022
2021
Net loss attributable to Cerus Corporation
$
(12,284
)
$
(17,457
)
Adjustments to net loss attributable to Cerus Corporation:
Net loss attributable to noncontrolling interest
—
—
Provision for income taxes
76
98
Total non-operating expense, net
2,360
912
Loss from operations
(9,848
)
(16,447
)
Adjustments to loss from operations:
Operating depreciation and amortization
1,079
959
Government contract revenue (i)
(5,576
)
(6,187
)
Direct expenses attributable to government contracts (ii)
4,258
4,901
Share-based compensation (iii)
6,426
5,333
Impairment
—
(62
)
Costs attributable to noncontrolling interest (iv)
—
—
Non-GAAP adjusted EBITDA
$
(3,661
)
$
(11,503
)
i.
Represents revenue related to the cost reimbursement provisions under our government contracts.
ii.
Represents the direct expenses attributable to work supporting government contracts, which are reimbursed and reflected under government contract revenue in the condensed consolidated statement of operations.
iii.
Represents non-cash stock-based compensation.
iv.
Represents costs associated with the noncontrolling interest in Cerus Zhongbaokang (Shandong) Biomedical Co., LTD.
